Merck posts mixed Q1 2026 results as blockbuster drugs drive growth
But acquisition charges drag earnings into loss
But acquisition charges drag earnings into loss
Wadhwa brings over two decades of experience driving growth, transformation, and customer-centric strategies in the medical devices and diagnostics sector
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
In his new role, Gregory will drive partnerships for the company’s large-scale molecule biologics business across Europe
Extending production capabilities to the Americas helps reduce labor costs and inventory complexity for nutraceuticals and other industries while maintaining superior moisture control
Strategic expansion strengthens CDMO’s support for biotech and pharma innovators across the Asia-Pacific region
Paves the way for next-gen ultra-precise gas sensing
The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation
The leading hospital chain appoints Lokesh Taridalu Shivakumar as Facility Director for Yeshwanthapur hospital
Subscribe To Our Newsletter & Stay Updated